<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3359">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388631</url>
  </required_header>
  <id_info>
    <org_study_id>2020-S073</org_study_id>
    <nct_id>NCT04388631</nct_id>
  </id_info>
  <brief_title>Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Detection Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Male Genitourinary System and Its Impact on Male Reproductive Health: an Observational Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the changes in sexual function, reproductive function and mental
      health of male patients discharged from the hospital with COVID-19, and the impact of
      SARS-CoV-2 on male reproductive health and mental health compared with healthy people during
      the same period. In addition, men's semen examination reports before and after the new
      coronavirus pneumonia event will be collected and compared to assess the impact of the event
      on the quality of men's semen. Also, This study will test the SARS-CoV-2 nucleic acid of the
      urogenital system of male patients discharged with COVID-19 to provide evidence for the
      effect of the new coronavirus on the male reproductive system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test SARS-CoV-2 nucleic acids in urine, prostate fluid, and semen of
      participants with COVID-19 at the first follow-up. All participants will be followed up for 1
      year. During follow-up, International Index of Erectile Function-5 (IIEF-5), Quality
      Evaluation Questionnaire (QEQ), symptom list chart-90 (SCL-90) questionnaire evaluation and
      sexual function related examinations (including nocturnal penile tumescence, color duplex
      ultrasonography, etc. ) and fertility-related examinations (including sex hormones, semen
      routine examinations, etc.) will be performed to assess the changes in male sexual function,
      reproductive function and mental health of male patients discharged with COVID-19, and the
      impact of SARS-CoV-2 on male reproductive and mental health. In addition, collect male semen
      examination reports from April to December in 2017-2020 to evaluate the impact of new
      coronavirus pneumonia incidents on male semen quality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Sperm density</measure>
    <time_frame>3 months</time_frame>
    <description>Sperm density will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sperm activity</measure>
    <time_frame>3 months</time_frame>
    <description>Sperm activity will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erection hardness and duration</measure>
    <time_frame>3 months</time_frame>
    <description>Erection hardness and duration will be evaluated during sleep by RigiscanHealth Organization (WHO) normal values based on the WHO 2010 reference limits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IIEF-5/QEQ questionnaire score</measure>
    <time_frame>3 months</time_frame>
    <description>IIEF-5/QEQ questionnaire score will be obtained by filling out the questionnaire every visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection rate of SARS-CoV-2 in male genitourinary system</measure>
    <time_frame>1 month</time_frame>
    <description>Detection rate of SARS-CoV-2 in male genitourinary system will be evaluated by real time-polymerase chain reaction (RT-PCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Semen volume</measure>
    <time_frame>3 months</time_frame>
    <description>Sperm volume will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sperm survival rate</measure>
    <time_frame>3 months</time_frame>
    <description>Sperm survival rate will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum testosterone/luteinizing hormone (LH)/follicle stimulating hormone (FSH) level</measure>
    <time_frame>3 months</time_frame>
    <description>The serum testosterone/LH/FSH levels will be tested in every visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCL-90 questionnaire score</measure>
    <time_frame>3 months</time_frame>
    <description>SCL-90 questionnaire score will be obtained using SCL-90 questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Height</measure>
    <time_frame>3 months</time_frame>
    <description>Height will be measured at every visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>3 months</time_frame>
    <description>Weight will be measured at every visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical classification of COVID-19</measure>
    <time_frame>1 month</time_frame>
    <description>Clinical classification of COVID-19 will be determined according to the New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National Health Commission of China</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>Exposed group</arm_group_label>
    <description>Male patient discharged with COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy male volunteers without COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coronavirus Disease 2019</intervention_name>
    <description>male patients who have developed COVID-19</description>
    <arm_group_label>Exposed group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood，serum，urine, prostate fluid, and semen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        male patients discharged with COVID-19 who have no previous sexual function and fertility
        related disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥ 18, ≤ 60 years old;

          2. Have a fixed sex partner and regular sex life;

          3. No previous infectious diseases, chronic diseases, tumor history, and male sexual
             function and fertility diseases;

          4. Normal erectile function, IIEF-5 score&gt; 21 points;

          5. Have complete clinical information and contact information；

          6. Understand and sign the informed consent form.

        Exclusion Criteria:

          1. Hypertension, diabetes, coronary heart disease, hyperlipidemia and other chronic
             diseases；

          2. Past history of endocrine diseases such as hypopituitarism, hypogonadism, abnormal
             thyroid function, etc;

          3. Past history of mumps virus infection;

          4. Past history of bladder cancer, prostate cancer, brain spine injury, testicular
             injury, pelvic fracture, urethral injury and history of surgical treatment;

          5. Severe cardiovascular and cerebrovascular diseases, severe lung diseases, severe
             hepatitis;

          6. Past psychological or mental illness;

          7. Contact information not available.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>all participants are male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departments of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Wang, M.D</last_name>
    <phone>027-83663640</phone>
    <email>tjhwt@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Wang, M.D</last_name>
      <email>tjhwt@126.com</email>
    </contact>
    <investigator>
      <last_name>Jihong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </reference>
  <reference>
    <citation>Douglas GC, O'Bryan MK, Hedger MP, Lee DK, Yarski MA, Smith AI, Lew RA. The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis. Endocrinology. 2004 Oct;145(10):4703-11. Epub 2004 Jul 1.</citation>
    <PMID>15231706</PMID>
  </reference>
  <reference>
    <citation>Xu J, Qi L, Chi X, Yang J, Wei X, Gong E, Peh S, Gu J. Orchitis: a complication of severe acute respiratory syndrome (SARS). Biol Reprod. 2006 Feb;74(2):410-6. Epub 2005 Oct 19.</citation>
    <PMID>16237152</PMID>
  </reference>
  <reference>
    <citation>Fraga-Silva RA, Costa-Fraga FP, Montecucco F, Sturny M, Faye Y, Mach F, Pelli G, Shenoy V, da Silva RF, Raizada MK, Santos RA, Stergiopulos N. Diminazene protects corpus cavernosum against hypercholesterolemia-induced injury. J Sex Med. 2015 Feb;12(2):289-302. doi: 10.1111/jsm.12757. Epub 2014 Nov 20.</citation>
    <PMID>25411084</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Jihong Liu</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Coronavirus Disease 2019</keyword>
  <keyword>Male reproductive health</keyword>
  <keyword>Mental health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measure will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available with 6 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the external independent review panel and Tongji hospital. Requester will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

